1
项与 Anti-BCMA|GPRC5D CAR-T (Xuzhou Medical University) 相关的临床试验Efficacy and Safety Study of Anti-BCMA/GPRC5D CAR-T Cells in Subjects With Relapsed and Refractory Multiple Myeloma
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-BCMA/GPRC5D CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture Anti-BCMA/GPRC5D chimeric antigen receptor (CAR) modified T cells. Prior to Anti-BCMA/GPRC5D infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
100 项与 Anti-BCMA|GPRC5D CAR-T (Xuzhou Medical University) 相关的临床结果
100 项与 Anti-BCMA|GPRC5D CAR-T (Xuzhou Medical University) 相关的转化医学
100 项与 Anti-BCMA|GPRC5D CAR-T (Xuzhou Medical University) 相关的专利(医药)
100 项与 Anti-BCMA|GPRC5D CAR-T (Xuzhou Medical University) 相关的药物交易